Stay updated on RSVPEDs Clinical Trial
Sign up to get notified when there's something new on the RSVPEDs Clinical Trial page.

Latest updates to the RSVPEDs Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe Study Locations section was updated to add numerous new sites across the US and internationally (e.g., California, Buenos Aires, New South Wales, Brașov, Târgu Mureș, etc.) and remove several existing sites, with a new Revision: v3.3.3 tag added.SummaryDifference1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check39 days agoChange DetectedRevision: v3.3.2 added. Revision: v3.2.0 removed.SummaryDifference0.0%

- Check46 days agoChange DetectedDeletion of a general government funding operating status notice from the page. This change does not affect the study details, eligibility criteria, or results information (To avoid being alerted by small changes, set an alert condition by clicking below).SummaryDifference0.2%

- Check60 days agoChange DetectedUpdated the Study Details page to include results reporting dates and last update timestamps, such as Results First Posted and results submission dates. The changes also introduce the Study Record Dates section with historical submission data.SummaryDifference0.3%

- Check89 days agoChange DetectedUpdated the page to v3.2.0 with a prominent notice about potential data/tansaction delays due to funding gaps and where to check operating status; previous v3.1.0 reference removed.SummaryDifference2%

- Check96 days agoChange DetectedThe page update adds a new version tag (v3.1.0) and removes several MedlinePlus topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) along with an older revision tag (v3.0.2), indicating a cleanup of outdated topics rather than adding new core content.SummaryDifference0.3%

Stay in the know with updates to RSVPEDs Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RSVPEDs Clinical Trial page.